Conflict of Interest: Many of the studies reviewed in this article were funded by Merck Research Laboratories. Drs. Hargreaves, Lines, and Ho are employees of Merck and own stock or stock options in Merck. Drs. Rapoport and Sheftell have received research funding from Merck and have acted as paid consultants for Merck.
Ten Years of Rizatriptan: From Development to Clinical Science and Future Directions
Article first published online: 21 JAN 2009
© 2009 the Authors. Journal compilation © 2009 American Headache Society
Headache: The Journal of Head and Face Pain
Special Issue: 10 Years of Rizatriptan
Volume 49, Issue Supplement s1, pages S3–S20, February 2009
How to Cite
Hargreaves, R. J., Lines, C. R., Rapoport, A. M., Ho, T. W. and Sheftell, F. D. (2009), Ten Years of Rizatriptan: From Development to Clinical Science and Future Directions. Headache: The Journal of Head and Face Pain, 49: S3–S20. doi: 10.1111/j.1526-4610.2008.01335.x
- Issue published online: 21 JAN 2009
- Article first published online: 21 JAN 2009
- Accepted for publication November 3, 2008.
- clinical science
The year 2008 marked the 10th anniversary since rizatriptan was first launched for the acute treatment of migraine. In this article we discuss the concepts that motivated the preclinical and clinical development of rizatriptan, the clinical evidence that has driven its use over the past decade, rizatriptan's overall contribution to the field, and future directions for research.